Eli Lilly has started a clinical trial to evaluate the safety of its automated insulin delivery system with Type 1 diabetes patients.
AID is part of the Connected Diabetes Ecosystem and acts as a platform to integrate an insulin pump and continuous glucose monitor.
“This trial is a significant step forward for Lilly’s Connected Care program, moving the Connected Diabetes Ecosystem closer to hopefully becoming available to the millions of people with diabetes who need a simpler, more effective way to use insulin,” said Marie Schiller, vice president, Connected Care and site head, Cambridge Innovation Center.
More clinical trials will be initiated in the coming months in both people with Type 1 and type 2 diabetes who use insulin, the company said. Lilly hopes to make these platforms available within 2 to 3 years, pending FDA approval.
